Paired Box 2 (PAX2) is a transcription factor that is essential for kidney development. In kidneys of normal adult, Pax2 protein expression is limited to nuclei of collecting ducts and to a lesser extent in distal tubules. PAX2 is expressed in early kidney organogenesis as well as in Wilms' tumor and renal cell carcinoma. PAX2 can be useful in the diagnosis of renal cell carcinoma.
This antibody is directed against a nuclear epitope present in human B lymphocytes. This antibody may be used to aid in the identification of normal and neoplastic cells of B-lymphocytic lineage.
PAX-8 (MRQ-50) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. This antibody is used subsequent to a clinical diagnosis of malignancy as an aid to determine if the disease can be classified as renal cell carcinoma, thyroid carcinoma, and ovarian non-mucinous carcinoma within the context of an antibody panel, the patient’s clinical history, and other diagnostic tests evaluated by a qualified pathologist.
Programmed death-1 (PD-1) is expressed on activated T-cells, B-cells, and myeloid cells. Anti-PD-1 is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm. Unlike CD10 and BCL6, PD-1 is expressed by few B-cells, so anti-PD-1 may be a more specific and useful diagnostic marker in angioimmunoblastic lymphoma. In addition, PD-1 expression provides evidence that angioimmunoblastic lymphoma is a neoplasm derived from germinal center-associated T-cells. PD-1 expression in angioimmunoblastic lymphoma lends further support to this model of T-cell oncogenesis, in which specific subtypes of T-cells may undergo neoplastic transformation and result in specific distinct histologic, immunophenotypic, and clinical subtypes of T-cell neoplasia. Programmed Death 1 (PD1) is expressed on most T-cells and a small subset of B-cells in the light zone of germinal centers and is a useful marker of angioimmunoblastic lymphoma.
PD-L1 IHC 22c3 is indicated as a companion diagnostic aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab) for cervical cancer, ES-SCLC, Gastric/Gastroesophageal cancer, head and neck cancer and NSCLC
PD-L1 IHC 28-8 is intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) and melanoma tissues.
The PD-L1 (SP142) Assay is used in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor infiltrating immune cells and is used as a companion diagnostic test for the use of Tecentriq in the treatment of melanoma, NSCLC, triple negative breast cancer and urothelial cell carcinoma.
The PD-L1 (SP263) Assay is used in the assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor infiltrating immune cells and is used as a companion diagnostic test for use of Imfinzi in the treatment of gastric/gastroesophageal carcinoma, melanoma, and urothelial carcinoma.
Testing uses bi-directional sequencing of exons 12 and 18 of the PDGFRA (platelet-derived growth factor alpha) gene. Solid tumor enrichment is performed before extraction. Gastrointestinal stromal tumors (GISTs) and some other soft tissue tumors frequently exhibit these exon mutation hotspots, accounting for most PDGFRA mutation including the common TKI-resistance mutation D842V.